Navigation Links
Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
Date:11/5/2013

PHILADELPHIA, Nov. 5, 2013 /PRNewswire/ -- Cohen, Placitella & Roth, PC is investigating claims on behalf of investors who purchased Ariad Pharmaceuticals, Inc. ("Ariad" or the "Company") (NASDAQ: ARIA) stock between December 11, 2011 and October 31, 2013, inclusive. The investigation concerns whether Ariad and certain of its officers and/or directors disseminated materially false and misleading information to investors in violation of Sections 10(b), and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, promulgated thereunder.

Ariad describes itself as an oncology company, focused on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer, and other difficult-to-treat cancers.  On October 9, 2013, Ariad disclosed that Iclusig, a drug the FDA approved in December, 2012 as a last-line treatment for certain kinds of chronic myeloid leukemia, had shown higher than expected rates of serious health problems related to blood clots. Two days later, the U.S. Food and Drug Administration announced it was investigating severe and life-threatening blood clots and narrowing of blood vessels in current patients taking the medication. On October 18, 2013 the Company announced it had agreed to terminate a trial of the drug in newly-diagnosed patients because arterial thrombotic events were observed in patients taking Iclusig. On October 31, 2013, at the FDA's request, the Company disclosed that it was suspending sales of the drug.

Upon its October 31, 2013, disclosure that it was suspending sales of Iclusig, Ariad shares declined $2.07 per share or over 3
'/>"/>

SOURCE Cohen, Placitella & Roth, PC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
2. UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
3. Clinical Trial Indicates Gabapentin Is Safe and Effective for Treating Alcohol Dependence
4. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
7. Soterix Medical Inc. announces Phase 3 Clinical Trial for Depression comparing tDCS-LTE against antidepressant drug (Escitalopram)
8. Langland Collaboration with CISCRP to Show Participants How Their Words Can Impact a Clinical Trial
9. InspireMD Schedules Conference Call to Discuss MASTER Trial 12-month Follow-Up Data
10. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
11. French Cost-Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 Concord Medical Services ... leading specialty hospital management solution provider and operator of the ... China , today announced it will release its ... market closes on August 17, 2015. Management will ... day, at 8:00 a.m. EDT on August 18, 2015 (8:00 ...
(Date:8/4/2015)... 2015 BioElectronics Corporation (OTC Pink: BIEL), ... Therapy medical devices, announced today that its registry ... trial device has been published in the prominent ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain ... assessment.  Chronic pain is a ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... its application in veterinary medicine and pharmaceuticals as ... animal genetics is important in the application of ...
Breaking Medicine Technology:Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3
... 1 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... obesity, today announced that the U.S. Food and Drug ... Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its ... is based on a substantial body of evidence gathered ...
... , IRVINE, Calif. , June 1 Cardiogenesis ... present at the Noble Financial Sixth Annual Equity Conference - ONTRACK ... Hollywood, Florida .  Executive Chairman Paul J. McCormick will ... at 5:00 pm Eastern Time ( 2:00 pm ...
Cached Medicine Technology:Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 2Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 3Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010 2
(Date:8/5/2015)... ... August 05, 2015 , ... ... world’s thickest and strongest tent for those with height restrictions. Gorilla Grow Tent ... finest materials in the tent construction, attention to detail and overall superiority in ...
(Date:8/5/2015)... ... August 05, 2015 , ... "Art de Toilettes" , ... employees to suggest ideas to add some fun and visual interest to the ... idea to transform toilets into works of art. Renew Life makes natural digestive ...
(Date:8/5/2015)... ... August 05, 2015 , ... Six major Moodle service ... (Moodlerooms, NetSpot and Remote-Learner UK) - have formed the Partners of Open source ... improve and streamline the process for Moodle plugin development, one of the most ...
(Date:8/5/2015)... ... August 05, 2015 , ... ... (“Frugal Financial”), a wholly-owned subsidiary. Frugal Financial is a registered investment advisor, serving ... complement and extend Employee Fiduciary’s core values and services , providing low-cost, ...
(Date:8/5/2015)... ... , ... Jvion’s CEO, Shantanu Nigam , was named Readers’ choice: 21 ... designation is given to those leaders who are enabling innovation within healthcare IT. Shantanu ... firm’s clinical predictive analytic solutions. , A spokesperson for Jvion said, “Since our inception, ...
Breaking Medicine News(10 mins):Health News:Best Grow Tent and Indoor Greenhouse Brand Gorilla Grow Tent Launches New Shorty Line 2Health News:Fantastic Team Spirit and Creativity Prevailed at Renew Life “Art de Toilettes” 2Health News:Moodle Service Providers to Simplify Moodle Plugin Development 2Health News:Moodle Service Providers to Simplify Moodle Plugin Development 3Health News:Moodle Service Providers to Simplify Moodle Plugin Development 4Health News:Employee Fiduciary Announces Subsidiary 2Health News:Jvion’s Shantanu Nigam Named One of the 21 Health IT Leaders to Know 2
... Web Site Strategy and Design, NEW YORK, ... been selected to develop a new web site ... of Public Health, one of the world,s,leading research, ... public health issues., "The Mailman website provides ...
... the,release of a new slimmer and more streamlined SenseWear(R) ... is 40% smaller than the previous model and weighs ... ergonomic,design intended to provide improved comfort and can be ... little device that could have a huge impact on,behavior ...
... Detroit bring up the rear, survey says , , MONDAY, May ... hearts in tip-top shape face the fewest challenges in Minneapolis, ... the list of the 10 most heart-healthy U.S. metropolitan areas ... But the list, released Monday by the American Heart Association, ...
... unnecessary surgeries , , MONDAY, May 19 (HealthDay News) ... lectin molecule called galectin-3 could help improve identification of ... surgeries, according to an Italian study. , The ... is to examine cells extracted by fine-needle aspiration. About ...
... survey says , , MONDAY, May 19 (HealthDay News) -- Women ... the fewest challenges in Minneapolis, Washington, D.C., and San Francisco. ... most heart-healthy U.S. metropolitan areas for women, a list that,s ... by the American Heart Association, also found the 10 metropolitan ...
... Disease Awareness Levels, However, ... More Doctor Visits Are Still Needed -, ... three,years, Hispanic-Americans have become increasingly aware of a potentially,serious ... Reflux Disease. Approximately 6.1 million Hispanics in the United,States ...
Cached Medicine News:Health News:Format-Studio Selected by Columbia University Mailman School of Public Health 2Health News:BodyMedia Releases New & Improved SenseWear(R) WMS Armband 2Health News:Minneapolis Tops List of Heart-Friendly Cities for Women 2Health News:Minneapolis Tops List of Heart-Friendly Cities for Women 3Health News:Protein Helps ID Thyroid Cancer Nodules 2Health News:Minneapolis Tops List of Heart-Healthy Cities for Women 2Health News:Minneapolis Tops List of Heart-Healthy Cities for Women 3Health News:New Survey Reveals Hispanic-Americans Are Taking Steps to Better Understand and Manage GERD 2Health News:New Survey Reveals Hispanic-Americans Are Taking Steps to Better Understand and Manage GERD 3Health News:New Survey Reveals Hispanic-Americans Are Taking Steps to Better Understand and Manage GERD 4Health News:New Survey Reveals Hispanic-Americans Are Taking Steps to Better Understand and Manage GERD 5
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
Treatment Strategies in Cardiovascular Medicine...
On the wards, on rounds, or at the bedside, clinicians can instantly access authoritative, up-to-date, practical guidelines for the immediate and long-term medical and surgical management of all card...
... Essentials of Diagnosis & Treatment in ... to diagnose and manage patients with ... treatment of 200 cardiac diseases, each ... the most pertinent information including: differential ...
Medicine Products: